INVITRO PHARMACODYNAMIC EVALUATION OF VP-16-213 AND IMPLICATIONS FOR CHEMOTHERAPY

被引：3

作者：

WOLFF, SN ^{[1
]}

GROSH, WW ^{[1
]}

PRATER, K ^{[1
]}

HANDE, KR ^{[1
]}

机构：

[1] VET ADM MED CTR,NASHVILLE,TN 37203

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1987年 / 19卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：246 / 249

页数：4

共 26 条

[1] A PHASE-I TRIAL OF CONTINUOUS INFUSION VP16-213 (ETOPOSIDE) [J].

AISNER, J ;

VANECHO, DA ;

WHITACRE, M ;

WIERNIK, PH .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 7 (2-3) :157-160

[2]

CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133

[3]

DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141

[4]

DOUPLE EB, 1985, CANCER-AM CANCER SOC, V56, P1918, DOI 10.1002/1097-0142(19851015)56:8<1918::AID-CNCR2820560804>3.0.CO

[5]

2-E

[6]

DOW LW, 1983, CANCER RES, V43, P5699

[7]

EVANS WE, 1982, CANCER CHEMOTH PHARM, V7, P147

[8]

HANDE KR, 1984, CANCER RES, V44, P379

[9] ETOPOSIDE (VP-16-213) [J].

ISSELL, BF ;

CROOKE, ST .

CANCER TREATMENT REVIEWS, 1979, 6 (02) :107-124

[10]

LOKICH J, 1981, CANCER TREAT REP, V65, P887

← 1 2 3 →